A detailed history of Snowden Capital Advisors LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Snowden Capital Advisors LLC holds 10,271 shares of NBIX stock, worth $1.29 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
10,271
Previous 10,371 0.96%
Holding current value
$1.29 Million
Previous $1.43 Million 1.12%
% of portfolio
0.04%
Previous 0.05%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$130.86 - $143.19 $13,086 - $14,319
-100 Reduced 0.96%
10,271 $1.41 Million
Q1 2024

May 15, 2024

SELL
$130.4 - $143.74 $60,114 - $66,264
-461 Reduced 4.26%
10,371 $1.43 Million
Q4 2023

Feb 14, 2024

BUY
$106.07 - $132.76 $67,990 - $85,099
641 Added 6.29%
10,832 $1.43 Million
Q3 2023

Nov 14, 2023

BUY
$94.02 - $117.1 $6,299 - $7,845
67 Added 0.66%
10,191 $1.15 Million
Q2 2023

Aug 14, 2023

BUY
$89.53 - $104.87 $467,973 - $548,155
5,227 Added 106.74%
10,124 $954,000
Q1 2023

May 15, 2023

BUY
$94.11 - $123.02 $7,340 - $9,595
78 Added 1.62%
4,897 $495,000
Q4 2022

Feb 13, 2023

SELL
$106.72 - $127.06 $67,340 - $80,174
-631 Reduced 11.58%
4,819 $575,000
Q3 2022

Nov 09, 2022

BUY
$92.03 - $107.81 $118,810 - $139,182
1,291 Added 31.04%
5,450 $578,000
Q2 2022

Aug 12, 2022

BUY
$75.79 - $100.07 $315,210 - $416,191
4,159 New
4,159 $405,000
Q3 2021

Feb 05, 2024

SELL
$86.18 - $99.03 $557,929 - $641,120
-6,474 Reduced 63.53%
3,717 $356 Million
Q2 2021

Jan 08, 2024

BUY
$89.43 - $102.27 $257,021 - $293,923
2,874 New
2,874 $280 Million
Q1 2020

Jan 08, 2024

SELL
$75.11 - $113.76 $4.16 Million - $6.3 Million
-55,400 Closed
0 $0
Q4 2019

Jan 08, 2024

BUY
$86.8 - $118.57 $520,800 - $711,420
6,000 Added 12.15%
55,400 $59.5 Million
Q3 2019

Jan 08, 2024

BUY
$83.82 - $101.5 $3.29 Million - $3.98 Million
39,209 Added 384.74%
49,400 $44.5 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Snowden Capital Advisors LLC Portfolio

Follow Snowden Capital Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Snowden Capital Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Snowden Capital Advisors LLC with notifications on news.